文献速递妇科

帕唑帕尼联合福斯布他林治疗复发性卵巢癌的1b期和随机2期试验

Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
PubMed 文献 · Gynecol Oncol · 2020-01-10

PAZOFOS试验评估帕唑帕尼联合福斯布他林治疗铂敏感复发性上皮性卵巢癌的安全性和疗效。1b期确定2期推荐剂量为福斯布他林54 mg/m2(第1、8、15天)联合帕唑帕尼600 mg每日一次;随机2期比较该联合方案与帕唑帕尼800 mg每日一次。

要点

  • 联合方案推荐剂量:福斯布他林54 mg/m2(d1,8,15)联合帕唑帕尼600 mg每日一次,每28天周期。
  • 联合组出现4例可逆性治疗相关心脏不良事件,导致研究提前终止。

核心结论

  • 帕唑帕尼联合福斯布他林治疗复发性上皮性卵巢癌的疗效尚不明确。
  • 未来试验需有效降低心脏风险以提高耐受性和患者安全。

研究设计与样本

  • 多中心1b期和开放标签随机2期试验(PAZOFOS)。
  • 纳入铂敏感复发性上皮性卵巢癌患者,无铂间期(PFI)3-12个月。
  • 按PFI(>6个月 vs ≤6个月)和既往贝伐珠单抗使用分层。

主要发现

  • 1b期最常见≥2级不良事件:高血压(100%)、中性粒细胞减少(50%)、乏力(50%)、呕吐(50%)。
  • 1b期出现1例剂量限制性毒性(3级乏力)。
  • 1b期和2期共4例接受联合治疗的患者出现可逆性治疗相关心脏不良事件,导致研究提前终止。

关键数值与推荐

  • 2期推荐剂量:福斯布他林54 mg/m2(第1、8、15天)联合帕唑帕尼600 mg每日一次,每28天周期。
  • 随机2期对照方案:帕唑帕尼800 mg每日一次。
  • 分层因素:无铂间期(>6个月 vs ≤6个月)和既往贝伐珠单抗使用。

临床怎么用

  • 该联合方案因心脏不良事件导致研究提前终止,目前不推荐常规临床使用。
  • 未来试验需建立有效的心脏风险缓解策略以提高耐受性和安全性。

局限性

  • 研究因心脏不良事件提前终止,可能影响疗效评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Vascular co-option is a resistance mechanism to anti-angiogenic agents, but combinations of anti-vascular agents may overcome this resistance. We report a phase 1b and randomised phase 2 trial to determine the safety and efficacy of pazopanib with fosbretabulin. METHODS: Eligible patients had recurrent, epithelial ovarian cancer with a platinum-free interval (PFI) of 3 to 12 months. Patients were stratified according to PFI (>6 versus ≤6 months) and prior bevacizumab use. RESULTS: Twelve patients were treated in the phase 1b. Commonest grade ≥ 2 adverse events (AEs) were hypertension (100%), neutropenia (50%), fatigue (50%), vomiting (50%). There was one DLT (grade 3 fatigue). The recommended phase 2 dose level was fosbretabulin 54 mg/m2 on days 1, 8 and 15 and pazopanib 600 mg once daily (od), every 28 days, which was then compared to pazopanib 800 mg od in a randomised phase 2 trial. Twenty-one patients were randomised (1:1) in the phase 2 trial. In phase 1b and phase 2, four patients treated with pazopanib and fosbretabulin developed reversible, treatment-related cardiac AEs, leading to premature discontinuation of the study. In the phase 2 trial, the median PFS was 7.6 months (95% CI 4.1-not estimated) versus 3.7 months (95% CI 1.0-8.1) in favour of the experimental arm (HR 0.30, 95% CI 0.09-1.03, P = .06). CONCLUSIONS: It remains unclear whether pazopanib with with fosbretabulin is an efficacious regimen to treat epithelial ovarian cancer. Effective cardiac risk mitigation is needed to increase the tolerability and maximize patient safety in future trials.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Morgan RD, Banerjee S, Hall M, et al. Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. Gynecol Oncol. 2020. PMID: 31932108. doi:10.1016/j.ygyno.2020.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。